Correction to: Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study

被引：0

作者：

Bei Wang

Rong Deng

Stefanie Hennig

Tanja Badovinac Crnjevic

Monika Kaewphluk

Matts Kågedal

Angelica L. Quartino

Sandhya Girish

Chunze Li

Whitney P. Kirschbrown

机构：

[1] Genentech,

[2] Inc.,undefined

[3] Certara,undefined

[4] Inc.,undefined

[5] F. Hoffmann-La Roche Ltd,undefined

[6] Clinical Pharmacology and Quantitative Pharmacology,undefined

[7] AstraZeneca,undefined

[8] Gilead Sciences,undefined

[9] Inc.,undefined

来源：

Cancer Chemotherapy and Pharmacology | 2022年 / 89卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：571 / 572

页数：1

共 50 条

[41] A historical controlled study of domestic trastuzumab and pertuzumab in combination with docetaxel for the neoadjuvant treatment of early HER2-positive breast cancer [J].

Xu, Dongdong ;

Wu, Jiang ;

Yu, Jing ;

Yang, Yuqing ;

Wen, Xinxin ;

Yang, Jixin ;

Wei, Hongliang ;

Xu, Xiaolong ;

Li, Yike ;

Yang, Liu ;

Wang, Lei ;

Wang, Yijia ;

Ma, Wen ;

Li, Nanlin .

FRONTIERS IN ONCOLOGY, 2024, 14

[42] Pertuzumab and trastuzumab as adjuvant treatment for HER2-positive early breast cancer: outcomes in Chinese patients in the APHINITY study [J].

Shao, Zhimin ;

Tseng, Ling-Ming ;

Huang, Chiun-Sheng ;

Pang, Da ;

Yang, Youngsen ;

Li, Wei ;

Liao, Ning ;

Geng, Cuizhi ;

Zhang, Qingyuan ;

Xu, Binghe ;

Liu, Donggeng ;

Kwong, Ava ;

Yu, Mandy ;

Sun, Guofang ;

Mobus, Volker ;

Dent, Susan ;

Arahmani, Amal ;

Borthwick, Gillian ;

Henot, Frederic ;

von Minckwitz, Gunter ;

Jiang, Zefei .

JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (03) :345-353

[43] ANALYSIS OF NON-PHARMACOLOGICAL COST SAVINGS DERIVED FROM THE USE OF FIXED- DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB FOR SUBCUTANEOUS INJECTION IN PATIENTS WITH HER2POSITIVE BREAST CANCER IN SPAIN [J].

Calleja, T. ;

Galve-Calvo, E. ;

Gomez Agudo, E. ;

Llaguno, J. L. ;

Martin Rufo, M. ;

Arroyo, I ;

Lagunar Ruiz, J. ;

Lores, M. ;

Monzon, M. ;

Saura, C. .

VALUE IN HEALTH, 2023, 26 (12) :S153-S153

[44] Pharmacokinetic and exposure–response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer [J].

Angelica L. Quartino ;

Hanbin Li ;

Jin Y. Jin ;

D. Russell Wada ;

Mark C. Benyunes ;

Virginia McNally ;

Lucia Viganò ;

Ihsan Nijem ;

Bert L. Lum ;

Amit Garg .

Cancer Chemotherapy and Pharmacology, 2017, 79 :353-361

[45] heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer [J].

Kuemmel, Sherko ;

Harper-Wynne, Catherine ;

Park, Yeon Hee ;

Franke, Fabio ;

de Laurentiis, Michelino ;

Schumacher-Wulf, Eva ;

Eiger, Daniel ;

Heeson, Sarah ;

Cardona, Andres ;

Ozyilkan, Ozgur ;

Morales-Vasquez, Flavia ;

Metcalfe, Ciara ;

Hafner, Marc ;

Restuccia, Eleonora ;

O'Shaughnessy, Joyce .

BMC CANCER, 2024, 24 (01)

[46] BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer [J].

Dang, Chau ;

Ewer, Michael S. ;

Delaloge, Suzette ;

Ferrero, Jean-Marc ;

Colomer, Ramon ;

de la Cruz-Merino, Luis ;

Werner, Theresa L. ;

Dadswell, Katherine ;

Verrill, Mark ;

Eiger, Daniel ;

Sarkar, Sriparna ;

de Haas, Sanne Lysbet ;

Restuccia, Eleonora ;

Swain, Sandra M. .

CANCERS, 2022, 14 (11)

[47] A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer [J].

De Cock, Erwin ;

Pivot, Xavier ;

Hauser, Nik ;

Verma, Sunil ;

Kritikou, Persefoni ;

Millar, Douglas ;

Knoop, Ann .

CANCER MEDICINE, 2016, 5 (03) :389-397

[48] Pharmacokinetic and exposure-response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer [J].

Kirschbrown, Whitney P. ;

Wang, Bei ;

Nijem, Ihsan ;

Ohtsu, Atsushi ;

Hoff, Paulo M. ;

Shah, Manish A. ;

Shen, Lin ;

Kang, Yoon-Koo ;

Alsina, Maria ;

Girish, Sandhya ;

Garg, Amit .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (03) :539-550

[49] Preliminary analysis of an expanded access study of the fixed-dose combination of pertuzumab (P) and trastuzumab (H) for subcutaneous injection (PH FDC SC) for at-home administration (admin) in patients (pts) with HER2-positive (HER2+) breast cancer (BC) during the COVID-19 pandemic. [J].

Dang, Chau T. ;

Tolaney, Sara M. ;

Riaz, Fauzia ;

Tan, Antoinette R. ;

Tkaczuk, Katherine H. R. ;

Yu, Anthony Francis ;

Liu, Jennifer ;

Fung, Anita M. ;

Yang, Anna ;

Day, Bann-Mo ;

Rugo, Hope S. .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

[50] White Paper on the Value of Time Savings for Patients and Healthcare Providers of Breast Cancer Therapy: The Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection as an Example COMMENT [J].

Jackisch, Christian ;

Manevy, Federico ;

Frank, Suzanne ;

Roberts, Nicki ;

Shafrin, Jason .

ADVANCES IN THERAPY, 2022, 39 (02) :833-844

← 1 2 3 4 5 →